Safety Watchdog Flags Ongoing Maternity Risks
The review comes after a series of high-profile scandals, including at Shrewsbury and Telford Hospital NHS Trust and Nottingham University Hospitals NHS Trust. The Shrewsbury inquiry, led by senior midwife Donna Ockenden, found that approximately 201 babies and nine mothers might have survived if they had received better care. The Nottingham review — also led by Ockenden — remains ongoing.
Safety Concerns and Baby Deaths
The HSSIB's latest report indicates that safety concerns persist. Between October 2023 and June 2025, the board received 35 reports of safety concerns in maternity or neonatal services. These accounted for about 10% of all safety concerns received during that period.
All cases involved "very serious harm", including 10 baby deaths. Sixteen incidents occurred during labour, and 12 during the neonatal period. Most reports came from women or family members, although some were submitted by healthcare staff.
Full Investigation Paused
The board had begun a scoping exercise to assess the need for a full investigation. However, the work was paused in June after the Secretary of State for Health and Social Care announced a national investigation into maternity and neonatal services, due to report in December 2025.
Health Secretary Wes Streeting said that multiple reviews into local trusts had found "similar failings in compassionate care" after maternity service failures "that should never have happened". He acknowledged "systemic" failings dating back more than 15 years and said families had been "gaslit" in their search for answers about their babies' deaths.
Although pausing its work, the HSSIB published its exploratory findings to support the national investigation. These were based on the 35 recent safety reports, meetings with 17 stakeholders, and a 2021 report by its precursor organisation, the Healthcare Safety Investigation Branch.
'Compounded Harms' to Families
The report identified 11 key themes. Progress had been made in maternity and neonatal outcomes, staffing levels, and governance, but disparities in care and outcomes persisted, partly due to health inequalities.
The HSSIB found that maternity and neonatal systems were overly complex, with inconsistent collaboration and poor information sharing. Local governance often operated in isolation, and services struggled to identify and respond to clinical risks or to learn from the harms that happened to women and babies during pregnancy, labour, and birth.
"Patients experience compounded harm due to issues within the wider healthcare system," the report concluded. It highlighted that local investigations, complaints processes, and legal proceedings such as inquests often caused additional harm. "Staff and trusts can lose sight of compassion during this process," it said.
Four Areas for Further Review
The HSSIB recommended four areas for potential further investigation:
National structures responsible for providing direction and oversight for maternity services.
Local governance and its relationship to national bodies.
Standards and approaches of local investigations when things go wrong.
Education, training, and professional standards for clinicians.
Staff Experience Cumulative Stress
The report said that maternity and neonatal staff also experienced cumulative stress and harm. It raised concerns about the standards set in undergraduate and postgraduate education, and whether these could be met in practice, noting that too many recommendations were being made, with limited implementation.
The HSSIB warned that multiple, high-profile maternity investigations and inquiries had eroded public confidence in maternity services. Some women were avoiding hospitals that had been the focus of national investigations, undermining recruitment and damaging staff morale.
The report cited instances of midwives receiving death threats or being berated for working in 'failing' services.
Stakeholders had told the HSSIB that clinicians had also become more risk-averse for fear of blame, a defensive approach that "drives the behaviour that compounds the harm women and families experience".
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
3 simple ways to spot fake weight loss jabs after Mounjaro price hike
With the price of Mounjaro set to almost triple in the UK, there are fears more and more people will turn to counterfeits. A former Big Brother star has said she "thought she was going to die" after taking a "fake" weight loss jab amid fears of a spike in black market demand as the price of Mounjaro is due to almost triple in the UK. Aisleyne Horgan Wallace told Good Morning Britain she suffered an adverse reaction when she bought the jab online. She said she temporarily lost her sight in one eye, suffered extreme vomiting and was in excruciating pain from the jab. Wallace said she took several doses before one left her bedridden and in and out of consciousness for several days. She has now warned about the dangers of counterfeit jabs after admitting it was a "foolish thing to do." Their high cost and limited availability have led to a flourishing black market for fake jabs. The National Pharmacy Association has warned about the risk of buying the jabs online without consulting a medical professional. In May, ITV News analysed some fake jabs they acquired at a "skinny jab party" and found they contained none of the active ingredients that contribute to weight loss. But there are fears that black market problems will get worse before they get better as Mounjaro's producer, Eli Lilly, is set to increase prices in the UK. Eli Lilly has said it will increase its prices in the UK from September after Donald Trump ramped up pressure on US pharmaceutical companies. The US president has promised to stop the disparity between what Americans pay for US-produced drugs compared to other countries, which often pay far less. The Rand Corporation think tank has said that US consumers pay three times more for drugs than in other developed countries. Trump has urged companies to close the gap and has threatened reprisals for those who do not do it voluntarily. There are fears that, rather than lowering the US price, drug companies will just raise their global price to meet Trump's demands, as appears to be the case with Eli Lilly. How much is Mounjaro increasing? Eli Lilly has said it will increase the price of the drug from September by 170%. A month's supply of the highest dose is rising from £122 to £330. Eli Lilly said the NHS would not pay for a higher price, so it will still be prescribed for people with obesity and type 2 diabetes. It will be the people who buy the jab privately through pharmacies or online stores that pay the higher price. The company has said private healthcare providers will be able to negotiate their own prices for purchasing the drug. Mounjaro is seen as the best weight-loss drug available by some, although Wegovy, made by Danish company Novodisk, has seen a huge surge in demand as a result of the price rises. A trial comparing the drugs found that people who took Mounjaro over 72 weeks lost 22.8kg compared to 15kg for people who took Wegovy. This has all led to a surge in people being uncompromising in their desire for Mounjaro and has led to many looking for alternative ways to secure their jabs. Medical professionals warn about people turning to counterfeits The price increase has led to people purchasing as many Mounjaro jabs as possible, but medical professionals have warned to be careful where you buy them from. Professor Claire Anderson, president of the Royal Pharmacist Society (RPS), told the Independent: "Counterfeit medicines from unregulated sources pose serious health risks - they can contain incorrect doses, harmful substances or no active ingredient at all." Jason Murphy, Head of Pharmacy at online retailer Chemist4U, said: "With the recent price hikes, we're likely to see more and more people turning to unregulated sellers because the medication may be cheaper. "This is extremely unsafe as many of these sources distribute counterfeit versions of Mounjaro, which pose serious risks to your health." The National Pharmacy Association has urged the government to improve regulation around online purchase of weight loss jabs to ensure people get the proper medical advice when buying them. How to spot fake weight loss jabs Chemist4U said there were three main identifiers to suggest a jab is fake. First, cost is a big one, the price of these jabs is set at certain points, with most retailers selling them at only a small profit. If you see one for considerably cheaper than normal, ask yourself how the seller got this from the manufacturer cheaper than large high street chains did. Secondly, currently in the UK Wegovy and Mounjaro are prescription-only medicines and can only be issued after a consultation. You can buy them from stores like Boots or Asda Pharmacy, but they will require a medical consultation first. If a vendor is selling them without this step, then you should steer clear of buying them. Finally, they will also look different. Chemist4U says "the materials used for real pens feel solid and well made, whereas a fake pen is likely to feel cheap, flimsy and have more obvious flaws like uneven colouring, rough edges or loose parts". They also point out that the real pens each have a unique serial number, whereas fake ones will not have one or a fake one.
Gizmodo
11 minutes ago
- Gizmodo
Ozempic Maker Novo Nordisk Freezes Hiring Amid Ongoing Struggles
No one stays on top forever. It's a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish pharmaceutical company has enacted a hiring freeze—the latest sign of a sinking financial outlook for the once-titan of the obesity treatment world. Reuters reported on the hiring freeze Wednesday. The company has faced numerous setbacks in recent months, including billions shaved off its stock market value and continued competition from cheaper, compounded versions of its blockbuster drug semaglutide. Though the freeze will apparently only apply to certain segments of the company, layoffs are likely not far off in the distance. 'We currently have a hiring freeze in non-business critical areas,' said Novo Nordisk in a statement to Reuters. Semaglutide is the active ingredient in Novo Nordisk's diabetes drug Ozempic and obesity medication Wegovy. It and similar compounds mimic the hormone GLP-1, which helps regulate insulin production and our appetite (among other functions). Though GLP-1 drugs have existed for two decades, semaglutide has proven more effective at helping people lose weight than diet and exercise alone, as well as other older medications. The approval of Wegovy in 2021 greatly reshaped the field of obesity medicine and earned plenty of money for Novo Nordisk. In 2024, the company reported about $42 billion dollars of revenue, driven by increasing sales of Wegovy and Ozempic (sometimes prescribed off-label for weight loss treatment). The company's success was so tremendous that it even helped bolster Denmark's local economy. But the company's meteoric rise has stumbled as of late for several reasons. For starters, it's no longer the only game in town, following the approval of Eli Lilly's tirzepatide for obesity (under the name Zepbound) in 2023. The drug, which combines GLP-1 with another weight-related hormone, is generally more effective than semaglutide, and people have steadily started to prefer it. Though Ozempic and Wegovy might still be more well known to the public, prescriptions of Zepbound in the U.S. now appear to be surpassing the former. Ozempic-Maker CEO Ousted Over Pharma Company's Rocky Market Downturn Novo Nordisk has also explicitly cited the emergence of the compounded drug market for GLP-1 therapy for its recent struggles. Compounded drugs are custom-made formulations of semaglutide and tirzepatide, often much cheaper, and produced by specialized pharmacies. The Food and Drug Administration has attempted to crack down on this industry, but many companies are still producing these drugs, and many people are still buying them. The fight over these compounded drugs has become so fierce that Novo Nordisk abruptly ended its newly formed partnership with telehealth company Hims in June. The company alleged that Hims was trying to deceptively market their compounded version of semaglutide over Wegovy to its users (Hims, for its part, has denied the accusation). These headwinds led Novo Nordisk to admit earlier this year that its projected sales growth in 2025 will fall short of past projections, which has since fueled further financial calamity. In May, the company fired its longtime CEO amid declining stocks. In July, investors wiped off $70 billion from the company's market value after it once again lowered its sales growth forecast for the remainder of the year. Sales of Wegovy and Ozempic do remain strong overall. And Novo Nordisk is developing other treatments intended to reclaim its throne in the obesity medicine field (including weight loss pills and drugs potentially more effective than any other treatment to date). But the company's fortunes are likely to worsen before they get better. Novo Nordisk Abruptly Ends Partnership with Hims, Claiming 'Sham Compounding' GLP-1 Drugs Departing CEO Lars Fruergaard Jørgensen stated in early August that the company, which currently employs nearly 80,000 people, will probably experience layoffs. The company's new CEO, Maziar Mike Doustdar, is also considering layoffs, according to a recent report from Danish TV2. This new era of obesity treatment isn't going anywhere anytime soon. But whether Novo Nordisk will remain the big dog on top is much more in question today than it would have been even just a few months ago.
Medscape
an hour ago
- Medscape
New First-Line Option for Advanced Bladder Cancer
The National Institute for Health and Care Excellence (NICE) has recommended the combination of enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) as a first-line option for adults with unresectable or metastatic urothelial cancer who are eligible for platinum-based chemotherapy. More than 1200 people in England are expected to benefit each year. Clinical experts described the combination therapy as a "step change" in bladder cancer management. Until now, treatment options for this patient group have seen little meaningful progress since the 1980s. Enfortumab vedotin is an antibody-drug conjugate consisting of an antibody targeting Nectin-4, a protein highly expressed in urothelial carcinoma cells. After binding, it causes the cells to release monomethyl auristatin E, resulting in cell death. Pembrolizumab, its combination partner, is a PD-1 inhibitor. High Disease Burden Urothelial cancer accounts for around 90% of bladder cancers, affecting more than 18,000 people annually in England. Prognosis is poor, with only 10% of patients with stage 4 disease surviving for 5 years or more. Current standard treatments include platinum-based chemotherapy ( cisplatin or carboplatin with gemcitabine), followed by avelumab maintenance therapy if the cancer has not progressed. However, only about 12% of patients see improvement with chemotherapy, underscoring the need for better options. Patient experts described living with metastatic urothelial cancer as "intensely challenging and emotionally exhausting', affecting work, travel, and physical activity. Action Bladder Cancer UK called the announcement a 'very welcome, and significant, step forward for this hard-to-treat cancer'. Clinical Evidence The recommendation in final draft guidance was supported by results from the phase 3 EV-302 trial, which enrolled 886 adults with untreated, unresectable, locally advanced, or metastatic urothelial cancer. Participants were randomly assigned in a 1:1 ratio to receive either enfortumab vedotin–pembrolizumab or standard chemotherapy. Enfortumab vedotin–pembrolizumab nearly doubled the median time to disease progression or death to 12.5 months, compared with 6.3 months for chemotherapy. Median overall survival was also improved, at 33.8 months versus 15.9 months with chemotherapy. Helen Knight, director of medicines evaluation at NICE, said the drug combination is 'highly promising and effective,' adding that these clinical trial results highlight the 'tremendous difference' it could make to the length and quality of people's lives. Cost and NHS Access Enfortumab vedotin is listed at £578 per 20 mg vial or £867 per 30 mg vial. Pembrolizumab costs £2630 per 100 mg vial, excluding VAT. The drugs will be supplied through confidential commercial arrangements with the NHS. NICE's appraisal committee applied a severity modifier, reflecting the high disease burden, and concluded that the therapy met acceptable cost-effectiveness thresholds. The treatment will be available immediately across the NHS in England, with funding required within 90 days of final publication of the guidance.
